Outcomes of mild cognitive impairment by definition: a population study

Mary Ganguli1, Beth E Snitz, Judith A Saxton

  • 1Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. gangulim@upmc.edu

Archives of Neurology
|June 15, 2011
PubMed
Abstract

Insights

Mild cognitive impairment (MCI) is heterogeneous, with varied progression and improvement rates across definitions. Population-level studies show lower dementia progression and higher recovery than clinical settings.

Area of Science:

  • Gerontology
  • Neuroscience
  • Epidemiology

Background:

  • Mild cognitive impairment (MCI) lacks a universally agreed-upon definition.
  • Understanding MCI's population-level outcomes is crucial for public health.

Purpose of the Study:

  • To assess the 1-year outcomes of mild cognitive impairment (MCI) using various definitions at the population level.
  • To compare progression, stability, and improvement rates across different MCI classifications.

Main Methods:

  • A 1-year inception cohort study of 1982 community-dwelling individuals aged 65+.
  • Participants were classified using multiple MCI definitions: Mayo criteria, International Working Group criteria, Clinical Dementia Rating (CDR) of 0.5, and cognitive domain-specific classifications.
  • Outcomes included progression to dementia (CDR ≥ 1), improvement to normal cognition (CDR = 0), or stability.

Main Results:

  • Regardless of definition, 0%-3% progressed to dementia (CDR > 1) and 0%-20% to severe cognitive impairment over 1 year.
  • Improvement to normal cognition occurred in 6%-53% of participants, with most (29%-92%) remaining stable.
  • MCI definitions emphasizing memory or multiple cognitive domains showed higher progression and lower improvement rates.

Conclusions:

  • Mild cognitive impairment (MCI) is a heterogeneous condition at the population level.
  • Dementia progression rates in MCI are higher than in cognitively normal individuals but lower than in clinical populations.
  • Memory-focused or multi-domain MCI classifications are associated with greater progression and less improvement, suggesting a need for community-level validation of research criteria.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...